Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common stock, par value $0.00001
-
Shares outstanding
-
53,185,766
-
Total 13F shares
-
55,249,345
-
Share change
-
+7,872,487
-
Total reported value
-
$1,150,065,944
-
Put/Call ratio
-
77%
-
Price per share
-
$20.82
-
Number of holders
-
98
-
Value change
-
+$162,099,243
-
Number of buys
-
48
-
Number of sells
-
47
Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (PMVP) as of Q1 2022
As of 31 Mar 2022,
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 (PMVP) was held by
98 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,249,345 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, MORGAN STANLEY, RTW INVESTMENTS, LP, BOXER CAPITAL, LLC, INTERWEST VENTURE MANAGEMENT CO, JPMORGAN CHASE & CO, VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, and Euclidean Capital LLC.
This page lists
98
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.